BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010;304:2154-2160. [PMID: 21081728 DOI: 10.1001/jama.2010.1672] [Cited by in Crossref: 306] [Cited by in F6Publishing: 277] [Article Influence: 27.8] [Reference Citation Analysis]
Number Citing Articles
1 Fujimaki S, Matsuda Y, Wakai T, Sanpei A, Kubota M, Takamura M, Yamagiwa S, Yano M, Ohkoshi S, Aoyagi Y. Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling. Cancer Lett 2012;319:98-108. [PMID: 22265862 DOI: 10.1016/j.canlet.2011.12.043] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
2 Klein J, Korol R, Lo SS, Chu W, Lock M, Dorth JA, Ellis RJ, Mayr NA, Huang Z, Chung HT. Stereotactic body radiotherapy: an effective local treatment modality for hepatocellular carcinoma. Future Oncol 2014;10:2227-41. [PMID: 25471036 DOI: 10.2217/fon.14.167] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
3 Kaneko S, Furuse J, Kudo M, Ikeda K, Honda M, Nakamoto Y, Onchi M, Shiota G, Yokosuka O, Sakaida I, Takehara T, Ueno Y, Hiroishi K, Nishiguchi S, Moriwaki H, Yamamoto K, Sata M, Obi S, Miyayama S, Imai Y. Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update. Hepatol Res 2012;42:523-42. [PMID: 22568457 DOI: 10.1111/j.1872-034X.2012.00981.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
4 Zeeneldin AA, Salem SE, Tabashy RH, Ibrahim AA, Alieldin NH. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a single center experience including 221 patients. J Egypt Natl Canc Inst 2013;25:143-50. [PMID: 23932751 DOI: 10.1016/j.jnci.2013.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
5 Kauffman MK, Kauffman ME, Zhu H, Jia Z, Li YR. Fluorescence-Based Assays for Measuring Doxorubicin in Biological Systems. React Oxyg Species (Apex) 2016;2:432-9. [PMID: 29707647 DOI: 10.20455/ros.2016.873] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
6 Schutz FA, Je Y, Richards CJ, Choueiri TK. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol. 2012;30:871-877. [PMID: 22312105 DOI: 10.1200/JCO.2011.37.1195] [Cited by in Crossref: 131] [Cited by in F6Publishing: 41] [Article Influence: 14.6] [Reference Citation Analysis]
7 Lou B, Fan J, Wang K, Chen W, Zhou X, Zhang J, Lin S, Lv F, Chen Y. N1-guanyl-1,7-diaminoheptane (GC7) enhances the therapeutic efficacy of doxorubicin by inhibiting activation of eukaryotic translation initiation factor 5A2 (eIF5A2) and preventing the epithelial-mesenchymal transition in hepatocellular carcinoma cells. Exp Cell Res. 2013;319:2708-2717. [PMID: 23958463 DOI: 10.1016/j.yexcr.2013.08.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
8 Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016;25:74-85. [PMID: 27312032 DOI: 10.1016/j.suronc.2016.03.002] [Cited by in Crossref: 165] [Cited by in F6Publishing: 172] [Article Influence: 33.0] [Reference Citation Analysis]
9 Welker MW, Trojan J. Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res 2013;5:337-47. [PMID: 24204170 DOI: 10.2147/CMAR.S35029] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
10 Abdel-rahman O, Fouad M. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis. Expert Review of Anticancer Therapy 2014;14:1063-73. [DOI: 10.1586/14737140.2014.929501] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
11 Ang C, O'Reilly EM, Abou-Alfa GK. Targeted agents and systemic therapy in hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:225-246. [PMID: 22941024 DOI: 10.1007/978-3-642-16037-0_15] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
12 Flores A, Marrero JA. Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol 2014;8:71-6. [PMID: 24899827 DOI: 10.4137/CMO.S9926] [Cited by in Crossref: 90] [Cited by in F6Publishing: 54] [Article Influence: 12.9] [Reference Citation Analysis]
13 Ady JW, Heffner J, Mojica K, Johnsen C, Belin LJ, Love D, Chen CT, Pugalenthi A, Klein E, Chen NG, Yu YA, Szalay AA, Fong Y. Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently. Surgery 2014;156:263-9. [PMID: 24957667 DOI: 10.1016/j.surg.2014.03.031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
14 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 267] [Article Influence: 30.3] [Reference Citation Analysis]
15 Sacco R, Bargellini I, Ginanni B, Bertini M, Bozzi E, Altomare E, Battaglia V, Romano A, Tumino E, Di Biase M, Bresci G, Bartolozzi C. Partial Response and Cardiovascular Recovery after Sorafenib Dose Reduction in a Multinodular HCC Patient. J Gastrointest Canc 2012;43:89-92. [DOI: 10.1007/s12029-011-9328-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Gutierrez JA, Gish RG. Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules. Transl Cancer Res 2013;2:460-71. [PMID: 26504748 DOI: 10.3978/j.issn.2218-676X.2013.10.01] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Ni H, Yang M, Guo Z, Zhang T. Sorafenib combined with cryoablation to treat unresectable hepatocellular carcinoma. Chin J Cancer Res 2011;23:188-93. [PMID: 23467380 DOI: 10.1007/s11670-011-0188-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
18 Hiramine Y, Uto H, Imamura Y, Tabu K, Baba Y, Hiwaki T, Sho Y, Tahara K, Higashi H, Tamai T. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study. Exp Ther Med. 2011;2:433-441. [PMID: 22977522 DOI: 10.3892/etm.2011.237] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
19 Ding F, Liu B, Wang Y. Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients. J Am Acad Dermatol. 2019;Online ahead of print. [PMID: 30991119 DOI: 10.1016/j.jaad.2019.04.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
20 Solorio L, Wu H, Hernandez C, Gangolli M, Exner AA. Ultrasound-guided intratumoral delivery of doxorubicin from in situ forming implants in a hepatocellular carcinoma model. Ther Deliv 2016;7:201-12. [PMID: 27010983 DOI: 10.4155/tde-2015-0008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
21 Suh SJ, Yim HJ. [Current status of molecular targeted therapies in hepatocellular carcinoma]. Korean J Gastroenterol 2013;61:136-46. [PMID: 23575232 DOI: 10.4166/kjg.2013.61.3.136] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
22 Wild AT, Gandhi N, Chettiar ST, Aziz K, Gajula RP, Williams RD, Kumar R, Taparra K, Zeng J, Cades JA. Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma. PLoS One. 2013;8:e65726. [PMID: 23762417 DOI: 10.1371/journal.pone.0065726] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
23 Chen KW, Ou TM, Hsu CW, Horng CT, Lee CC, Tsai YY, Tsai CC, Liou YS, Yang CC, Hsueh CW, Kuo WH. Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol 2015; 7(10): 1412-1420 [PMID: 26052386 DOI: 10.4254/wjh.v7.i10.1412] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
24 da Motta Girardi D, Correa TS, Crosara Teixeira M, Dos Santos Fernandes G. Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. J Gastrointest Canc 2018;49:227-36. [DOI: 10.1007/s12029-018-0121-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 5.7] [Reference Citation Analysis]
25 Totzeck M, Mincu R, Mrotzek S, Schadendorf D, Rassaf T. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiolog 2018;25:482-94. [DOI: 10.1177/2047487318755193] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
26 Abdelgalil AA, Alkahtani HM, Al-jenoobi FI. Sorafenib. Elsevier; 2019. pp. 239-66. [DOI: 10.1016/bs.podrm.2018.11.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
27 Wang J, Ma L, Tang X, Zhang X, Qiao Y, Shi Y, Xu Y, Wang Z, Yu Y, Sun F. Doxorubicin induces apoptosis by targeting Madcam1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells. Oncotarget 2015;6:24075-91. [PMID: 26124182 DOI: 10.18632/oncotarget.4373] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
28 Khanna R, Verma SK. Pediatric hepatocellular carcinoma. World J Gastroenterol 2018; 24(35): 3980-3999 [PMID: 30254403 DOI: 10.3748/wjg.v24.i35.3980] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 33] [Article Influence: 14.7] [Reference Citation Analysis]
29 Liu Z, Tang X, Feng F, Xu J, Wu C, Dai G, Yue W, Zhong W, Xu K. Molecular design of peptide amphiphiles for controlled self-assembly and drug release. J Mater Chem B 2021;9:3326-34. [PMID: 33881438 DOI: 10.1039/d1tb00173f] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Chan SL. Drug development for hepatocellular carcinoma: knowing the past helps to understand the future. Oncologist. 2014;19:1115-1117. [PMID: 25223461 DOI: 10.1634/theoncologist.2014-0304] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
31 Qin S, Cheng Y, Liang J, Shen L, Bai Y, Li J, Fan J, Liang L, Zhang Y, Wu G. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist. 2014;19:1169-1178. [PMID: 25223462 DOI: 10.1634/theoncologist.2014-0190] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
32 Hoffmann AC, Gerken GG. Hepatocellular Cancer: New Kids on the Block. Gastrointest Tumors 2014;1:195-200. [PMID: 26676221 DOI: 10.1159/000380787] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
33 Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR Jr, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JH, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. JAMA Oncol. 2019;. [PMID: 31486832 DOI: 10.1001/jamaoncol.2019.2792] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 17.0] [Reference Citation Analysis]
34 Kalyan A, Nimeiri H, Kulik L. Systemic therapy of hepatocellular carcinoma: current and promising. Clin Liver Dis 2015;19:421-32. [PMID: 25921671 DOI: 10.1016/j.cld.2015.01.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
35 Wei Z, Doria C, Liu Y. Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol 2013;7:87-102. [PMID: 23761989 DOI: 10.4137/CMO.S7633] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
36 Yaghmai V, Besa C, Kim E, Gatlin JL, Siddiqui NA, Taouli B. Imaging Assessment of Hepatocellular Carcinoma Response to Locoregional and Systemic Therapy. American Journal of Roentgenology 2013;201:80-96. [DOI: 10.2214/ajr.13.10706] [Cited by in Crossref: 53] [Cited by in F6Publishing: 18] [Article Influence: 6.6] [Reference Citation Analysis]
37 Chang Y, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH. CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. BMC Cancer 2020;20:1001. [PMID: 33059615 DOI: 10.1186/s12885-020-07471-3] [Reference Citation Analysis]
38 Kovacovicova K, Skolnaja M, Heinmaa M, Mistrik M, Pata P, Pata I, Bartek J, Vinciguerra M. Senolytic Cocktail Dasatinib+Quercetin (D+Q) Does Not Enhance the Efficacy of Senescence-Inducing Chemotherapy in Liver Cancer. Front Oncol 2018;8:459. [PMID: 30425964 DOI: 10.3389/fonc.2018.00459] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
39 Lin J, Wu L, Bai X, Xie Y, Wang A, Zhang H, Yang X, Wan X, Lu X, Sang X, Zhao H. Combination treatment including targeted therapy for advanced hepatocellular carcinoma. Oncotarget 2016;7:71036-51. [PMID: 27626176 DOI: 10.18632/oncotarget.11954] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
40 Zhang X, Yang XR, Huang XW, Wang WM, Shi RY, Xu Y, Wang Z, Qiu SJ, Fan J, Zhou J. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int. 2012;11:458-466. [PMID: 23060390 DOI: 10.1016/s1499-3872(12)60209-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
41 Mattina J, Carlisle B, Hachem Y, Fergusson D, Kimmelman J. Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLoS Biol 2017;15:e2000487. [PMID: 28158308 DOI: 10.1371/journal.pbio.2000487] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
42 Poon RT, Cheung TT, Kwok PC, Lee AS, Li TW, Loke KL, Chan SL, Cheung MT, Lai TW, Cheung CC. Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer. 2015;4:51-69. [PMID: 26020029 DOI: 10.1159/000367728] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
43 Ma Q, Gu LY, Ren YY, Zeng LL, Gong T, Zhong DS. Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis. Onco Targets Ther 2015;8:2361-74. [PMID: 26355897 DOI: 10.2147/OTT.S87298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
44 Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz J. Hepatocellular Carcinoma: Current Management and Perspectives for the Future. Annals of Surgery 2011;253:453-69. [DOI: 10.1097/sla.0b013e31820d944f] [Cited by in Crossref: 282] [Cited by in F6Publishing: 170] [Article Influence: 28.2] [Reference Citation Analysis]
45 Konstantinidis IT, Do RK, Gultekin DH, Gönen M, Schwartz LH, Fong Y, Allen PJ, D’Angelica MI, DeMatteo RP, Klimstra DS. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol. 2014;21:2675-2683. [PMID: 24664624 DOI: 10.1245/s10434-014-3649-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
46 Dranitsaris G, Vincent MD, Yu J, Huang L, Fang F, Lacouture ME. Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. Ann Oncol 2012;23:2103-8. [PMID: 22228446 DOI: 10.1093/annonc/mdr580] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
47 Assenat E, Pageaux GP, Thézenas S, Peron JM, Bécouarn Y, Seitz JF, Merle P, Blanc JF, Bouché O, Ramdani M, Poujol S, de Forges H, Ychou M, Boige V. Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial. Br J Cancer 2019;120:896-902. [PMID: 30944458 DOI: 10.1038/s41416-019-0443-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
48 Geier A, Schadde E, Müllhaupt B. [Current therapeutic strategies for hepatocellular carcinoma]. MMW Fortschr Med 2012;154:63-7; quiz 68-9. [PMID: 22957387 DOI: 10.1007/s15006-012-0931-4] [Reference Citation Analysis]
49 Chen W, Hu QD, Xia XF, Liang C, Liu H, Zhang Q, Ma T, Liang F, Liang TB. Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells. Cancer Biol Ther 2014;15:992-9. [PMID: 24800850 DOI: 10.4161/cbt.29113] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
50 Ikeda M, Mitsunaga S, Ohno I, Hashimoto Y, Takahashi H, Watanabe K, Umemoto K, Okusaka T. Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future. Diseases 2015;3:360-81. [PMID: 28943630 DOI: 10.3390/diseases3040360] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
51 Keane FK, Hong TS, Zhu AX. Evolving Systemic Therapy in Hepatocellular Carcinoma: Current Management and Opportunities for Integration With Radiotherapy. Semin Radiat Oncol 2018;28:332-41. [PMID: 30309643 DOI: 10.1016/j.semradonc.2018.06.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
52 Cabibbo G, Celsa C, Enea M, Battaglia S, Rizzo GEM, Busacca A, Matranga D, Attanasio M, Reig M, Craxì A, Cammà C. Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. Cancers (Basel) 2020;13:E90. [PMID: 33396833 DOI: 10.3390/cancers13010090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Ikeda M, Shiina S, Nakachi K, Mitsunaga S, Shimizu S, Kojima Y, Ueno H, Morizane C, Kondo S, Sakamoto Y, Asaoka Y, Tateishi R, Koike K, Arioka H, Okusaka T. Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma. Invest New Drugs 2014;32:928-36. [PMID: 24829073 DOI: 10.1007/s10637-014-0109-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
54 Hollebecque A, Malka D, Ferté C, Ducreux M, Boige V. Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons. Eur J Cancer. 2015;51:327-339. [PMID: 25559615 DOI: 10.1016/j.ejca.2014.12.005] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
55 Liu K, Zhang X, Xu W, Chen J, Yu J, Gamble JR, McCaughan GW. Targeting the vasculature in hepatocellular carcinoma treatment: Starving vs normalizing blood supply.Clin Transl Gastroenterol. 2017;8:e98. [DOI: 10.1038/ctg.2017.28] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 10.5] [Reference Citation Analysis]
56 Kohorst MA, Warad DM, Matsumoto JM, Heimbach JK, El-Youssef M, Arndt CAS, Rodriguez V, Nageswara Rao AA. Management of pediatric hepatocellular carcinoma: A multimodal approach. Pediatr Transplant 2017;21. [PMID: 28631359 DOI: 10.1111/petr.13007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
57 Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem. 2011;3:1787-1808. [PMID: 22004085 DOI: 10.4155/fmc.11.121] [Cited by in Crossref: 266] [Cited by in F6Publishing: 246] [Article Influence: 29.6] [Reference Citation Analysis]
58 Chen X, Zhang X, Zhang L, Zhao G, Xu S, Li L, Su Z, Liu R, Wang C. An EPR-independent therapeutic strategy: Cancer cell-mediated dual-drug delivery depot for diagnostics and prevention of hepatocellular carcinoma metastasis. Biomaterials 2021;268:120541. [DOI: 10.1016/j.biomaterials.2020.120541] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Breeta RDIE, Grace VMB, Wilson DD. Methyl Palmitate-A suitable adjuvant for Sorafenib therapy to reduce in vivo toxicity and to enhance anti-cancer effects on hepatocellular carcinoma cells. Basic Clin Pharmacol Toxicol 2021;128:366-78. [PMID: 33128309 DOI: 10.1111/bcpt.13525] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Cox J, Weinman S. Mechanisms of doxorubicin resistance in hepatocellular carcinoma. Hepat Oncol. 2016;3:57-59. [PMID: 26998221 DOI: 10.2217/hep.15.41] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 11.4] [Reference Citation Analysis]
61 Liu B, Ding F, Liu Y, Xiong G, Lin T, He D, Zhang Y, Zhang D, Wei G. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget 2016;7:67661-73. [PMID: 27602778 DOI: 10.18632/oncotarget.11813] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
62 Abou-alfa GK, Marrero J, Renz J, Lencioni R. Hepatocellular Carcinoma Tumor Board: Making Sense of the Technologies. American Society of Clinical Oncology Educational Book 2015. [DOI: 10.14694/edbook_am.2015.35.e213] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
63 Yang X, Pan X, Cheng X, Cheng Y, Kuang Y. Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death. Int J Clin Pharm 2015;37:1047-56. [PMID: 26173936 DOI: 10.1007/s11096-015-0151-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
64 Ma K, He Y, Zhang H, Fei Q, Niu D, Wang D, Ding X, Xu H, Chen X, Zhu J. DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem. 2012;287:5639-5649. [PMID: 22117060 DOI: 10.1074/jbc.m111.291229] [Cited by in Crossref: 82] [Cited by in F6Publishing: 59] [Article Influence: 8.2] [Reference Citation Analysis]
65 Cao H, Wang Y, He X, Zhang Z, Yin Q, Chen Y, Yu H, Huang Y, Chen L, Xu M, Gu W, Li Y. Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma. Mol Pharm 2015;12:922-31. [PMID: 25622075 DOI: 10.1021/mp500755j] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 9.5] [Reference Citation Analysis]
66 Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: Present and future: Novel treatment for liver cancer. Journal of Gastroenterology and Hepatology 2012;27:862-72. [DOI: 10.1111/j.1440-1746.2012.07096.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 6.2] [Reference Citation Analysis]
67 Funakoshi T, Latif A, Galsky MD. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. J Hum Hypertens 2013;27:601-11. [DOI: 10.1038/jhh.2013.30] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
68 Han Y, Zhi WH, Xu F, Zhang CB, Huang XQ, Luo JF. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. World J Gastroenterol 2021; 27(19): 2415-2433 [PMID: 34040331 DOI: 10.3748/wjg.v27.i19.2415] [Reference Citation Analysis]
69 Pazo-Cid RA, Lanzuela M, Esquerdo G, Pérez-Gracia JL, Antón A, Amigo G, Trufero JM, García-Otín AL, Martín-Duque P. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). Clin Transl Oncol 2012;14:564-74. [PMID: 22855137 DOI: 10.1007/s12094-012-0842-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
70 Hsu C, Chen BB, Chen CH, Ho MC, Cheng JC, Kokudo N, Murakami T, Yeo W, Seong J, Jia JD. Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer. 2015;4:96-105. [PMID: 26020032 DOI: 10.1159/000367732] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
71 Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3:424-432. [PMID: 29631810 DOI: 10.1016/s2468-1253(18)30078-5] [Cited by in Crossref: 75] [Cited by in F6Publishing: 52] [Article Influence: 25.0] [Reference Citation Analysis]
72 Balasso A, Salmaso S, Pontisso P, Rosato A, Quarta S, Malfanti A, Mastrotto F, Caliceti P. Re-programming pullulan for targeting and controlled release of doxorubicin to the hepatocellular carcinoma cells. European Journal of Pharmaceutical Sciences 2017;103:104-15. [DOI: 10.1016/j.ejps.2017.02.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
73 Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(34): 7645-7659 [PMID: 27678348 DOI: 10.3748/wjg.v22.i34.7645] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 72] [Article Influence: 14.4] [Reference Citation Analysis]
74 Nagel C, Armeanu-ebinger S, Dewerth A, Warmann SW, Fuchs J. Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma. Experimental Cell Research 2015;331:97-104. [DOI: 10.1016/j.yexcr.2014.10.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
75 da Fonseca LG, Marta GN, Braghiroli MIFM, Chagas AL, Carrilho FJ, Hoff PM, Sabbaga J. Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib. BMC Cancer 2018;18:1250. [PMID: 30545331 DOI: 10.1186/s12885-018-5173-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
76 Abou-Alfa GK, Venook AP. The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached? Lancet Oncol. 2013;14:e283-e288. [PMID: 23725711 DOI: 10.1016/s1470-2045(13)70161-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
77 Yadav A, Kumar B, Teknos TN, Kumar P. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther. 2011;10:1241-1251. [PMID: 21551262 DOI: 10.1158/1535-7163.mct-11-0004] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
78 Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys. 2013;87:22-32. [PMID: 23219567 DOI: 10.1016/j.ijrobp.2012.08.043] [Cited by in Crossref: 115] [Cited by in F6Publishing: 102] [Article Influence: 12.8] [Reference Citation Analysis]
79 Oranratnachai S, Rattanasiri S, Pooprasert A, Tansawet A, Reungwetwattana T, Attia J, Thakkinstian A. Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:654020. [PMID: 33869060 DOI: 10.3389/fonc.2021.654020] [Reference Citation Analysis]
80 Asghar U, Meyer T. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol. 2012;56:686-695. [PMID: 21971559 DOI: 10.1016/j.jhep.2011.07.031] [Cited by in Crossref: 114] [Cited by in F6Publishing: 112] [Article Influence: 11.4] [Reference Citation Analysis]
81 Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. Crit Rev Oncol Hematol. 2014;91:1-8. [PMID: 24457121 DOI: 10.1016/j.critrevonc.2013.12.013] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
82 Niu L, Liu L, Yang S, Ren J, Lai PBS, Chen GG. New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies. Biochim Biophys Acta Rev Cancer. 2017;1868:564-570. [PMID: 29054475 DOI: 10.1016/j.bbcan.2017.10.002] [Cited by in Crossref: 72] [Cited by in F6Publishing: 87] [Article Influence: 18.0] [Reference Citation Analysis]
83 Esposito V, Verdina A, Manente L, Spugnini EP, Viglietti R, Parrella R, Pagliano P, Parrella G, Galati R, De Luca A, Baldi A, Montesarchio V, Chirianni A. Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts. J Cell Physiol 2013;228:640-5. [DOI: 10.1002/jcp.24173] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
84 Meng MB, Zaorsky NG, Deng L, Wang HH, Chao J, Zhao LJ, Yuan ZY, Ping W. Pericytes: a double-edged sword in cancer therapy. Future Oncol 2015;11:169-79. [PMID: 25143028 DOI: 10.2217/fon.14.123] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
85 Park JW, Kim YJ, Kim DY, Bae SH, Paik SW, Lee YJ, Kim HY, Lee HC, Han SY, Cheong JY, Kwon OS, Yeon JE, Kim BH, Hwang J. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. J Hepatol. 2019;70:684-691. [PMID: 30529387 DOI: 10.1016/j.jhep.2018.11.029] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 17.0] [Reference Citation Analysis]
86 Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. Future Oncol 2014;10:1981-92. [PMID: 25386814 DOI: 10.2217/fon.14.42] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
87 Inagaki Y, Kokudo T, Kamiya M, Uno SN, Sato M, Kaneko J, Kokudo N, Urano Y, Hasegawa K. A novel liver-specific fluorescent anti-cancer drug delivery system using indocyanine green. Sci Rep 2019;9:3044. [PMID: 30816163 DOI: 10.1038/s41598-019-39269-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
88 Rafiullah, Ali A, Mohiuddin H, Zahid U, Abushahin L. Innovations in the Management of Hepatocellular Carcinoma. American Journal of Therapeutics 2018;25:e362-8. [DOI: 10.1097/mjt.0000000000000713] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
89 Helmy SA, El-Mesery M, El-Karef A, Eissa LA, El Gayar AM. Chloroquine upregulates TRAIL/TRAILR2 expression and potentiates doxorubicin anti-tumor activity in thioacetamide-induced hepatocellular carcinoma model. Chem Biol Interact 2018;279:84-94. [PMID: 29133031 DOI: 10.1016/j.cbi.2017.11.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
90 Xiang QF, Zhang DM, Wang JN, Zhang HW, Zheng ZY, Yu DC, Li YJ, Xu J, Chen YJ, Shang CZ. Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein. Liver Int. 2015;35:1010-1023. [PMID: 24621440 DOI: 10.1111/liv.12524] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
91 Zhu AX. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol. 2012;39:493-502. [PMID: 22846866 DOI: 10.1053/j.seminoncol.2012.05.014] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 6.9] [Reference Citation Analysis]
92 Ang C, Miura JT, Gamblin TC, He R, Xiu J, Millis SZ, Gatalica Z, Reddy SK, Yee NS, Abou-Alfa GK. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options. J Surg Oncol. 2016;113:55-61. [PMID: 26661118 DOI: 10.1002/jso.24086] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
93 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 310] [Article Influence: 31.0] [Reference Citation Analysis]
94 Wu WD, Chen PS, Omar HA, Arafa EA, Pan HW, Jeng J, Hung JH. Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma. Sci Rep 2018;8:12914. [PMID: 30150684 DOI: 10.1038/s41598-018-31209-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
95 Liao R, Zhang XD, Li GZ, Qin KL, Yan X. Comparison of transcatheter arterial chemoembolization with raltitrexed plus liposomal doxorubicin vs. tegafur plus pirarubicin for unresectable hepatocellular carcinoma. J Gastrointest Oncol 2020;11:747-59. [PMID: 32953158 DOI: 10.21037/jgo-20-59] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
96 Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/Leucovorin vs doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31:3501-3508. [PMID: 23980077 DOI: 10.1200/jco.2012.44.5643] [Cited by in Crossref: 218] [Cited by in F6Publishing: 139] [Article Influence: 27.3] [Reference Citation Analysis]
97 Kumari R, Sahu MK, Tripathy A, Uthansingh K, Behera M. Hepatocellular carcinoma treatment: hurdles, advances and prospects. Hepat Oncol 2018;5:HEP08. [PMID: 31293776 DOI: 10.2217/hep-2018-0002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
98 Choi YH, Zhang C, Liu Z, Tu MJ, Yu AX, Yu AM. A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine In Vivo Synergism. J Pharmacol Exp Ther 2021;377:305-15. [PMID: 33712506 DOI: 10.1124/jpet.121.000584] [Reference Citation Analysis]
99 Raza A, Sood GK. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol 2014; 20(15): 4115-4127 [PMID: 24764650 DOI: 10.3748/wjg.v20.i15.4115] [Cited by in CrossRef: 237] [Cited by in F6Publishing: 221] [Article Influence: 33.9] [Reference Citation Analysis]
100 Huntington JT, Tang X, Kent LN, Schmidt CR, Leone G. The Spectrum of E2F in Liver Disease--Mediated Regulation in Biology and Cancer. J Cell Physiol 2016;231:1438-49. [PMID: 26566968 DOI: 10.1002/jcp.25242] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
101 Germano D, Daniele B. Systemic therapy of hepatocellular carcinoma: Current status and future perspectives. World J Gastroenterol 2014; 20(12): 3087-3099 [PMID: 24696596 DOI: 10.3748/wjg.v20.i12.3087] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
102 Ghatalia P, Morgan CJ, Je Y, Nguyen PL, Trinh Q, Choueiri TK, Sonpavde G. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology 2015;94:228-37. [DOI: 10.1016/j.critrevonc.2014.12.008] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 11.2] [Reference Citation Analysis]
103 Samonakis DN, Kouroumalis EA. Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol 2017; 9(2): 80-90 [PMID: 28144389 DOI: 10.4254/wjh.v9.i2.80] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
104 Gras P, Truant S, Boige V, Ladrat L, Rougier P, Pruvot FR, Hebbar M. Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma. Case Rep Oncol. 2012;5:169-172. [PMID: 22666208 DOI: 10.1159/000338242] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
105 Ali HEA, Emam AA, Zeeneldin AA, Srour R, Tabashy R, El-Desouky ED, Abd Elmageed ZY, Abdel-Wahab AA. Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization. Clin Biochem 2019;65:45-52. [PMID: 30653948 DOI: 10.1016/j.clinbiochem.2019.01.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
106 Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, McKeegan EM, Dowell B, Pedersen M, Qin Q, Qian J, Scappaticci FA, Ricker JL, Carlson DM, Yong WP. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer. 2013;119:380-387. [PMID: 22833179 DOI: 10.1002/cncr.27758] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 7.7] [Reference Citation Analysis]
107 Di Maio M, Daniele G, Piccirillo MC, Giordano P, Signoriello G, Daniele B, Perrone F. Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials. Cancers (Basel) 2012;4:549-65. [PMID: 24213324 DOI: 10.3390/cancers4020549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
108 Feng YM, Feng CW, Lu CL, Lee MY, Chen CY, Chen SC. Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients. Jpn J Clin Oncol 2015;45:336-42. [PMID: 25646358 DOI: 10.1093/jjco/hyv007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
109 Feng J, Dai W, Mao Y, Wu L, Li J, Chen K, Yu Q, Kong R, Li S, Zhang J, Ji J, Wu J, Mo W, Xu X, Guo C. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis. J Exp Clin Cancer Res 2020;39:24. [PMID: 32000827 DOI: 10.1186/s13046-020-1528-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 22.0] [Reference Citation Analysis]
110 Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma 2017;4:93-103. [PMID: 28744453 DOI: 10.2147/JHC.S106529] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
111 Piñero F, Silva M, Iavarone M. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. World J Gastroenterol 2020; 26(16): 1888-1900 [PMID: 32390700 DOI: 10.3748/wjg.v26.i16.1888] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
112 Kou P, Zhang Y, Shao W, Zhu H, Zhang J, Wang H, Kong L, Yu J. Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. Oncotarget 2017;8:20510-5. [PMID: 28103584 DOI: 10.18632/oncotarget.14724] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
113 Newgard BJ, Getrajdman GI, Erinjeri JP, Covey AM, Brody LA, Sofocleous CT, Brown KT. Incidence and Consequence of Nontarget Embolization Following Bland Hepatic Arterial Embolization. Cardiovasc Intervent Radiol 2019;42:1135-41. [DOI: 10.1007/s00270-019-02229-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
114 Sohal DP, Sun W. Hepatocellular carcinoma: prevention and therapy. Curr Oncol Rep. 2011;13:186-194. [PMID: 21409527 DOI: 10.1007/s11912-011-0165-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
115 Dou Y, Hynynen K, Allen C. To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes. Journal of Controlled Release 2017;249:63-73. [DOI: 10.1016/j.jconrel.2017.01.025] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 19.5] [Reference Citation Analysis]
116 Gao F, Zhang C, Qiu W, Dong X, Zheng D, Wu W, Zhang X. PD-1 Blockade for Improving the Antitumor Efficiency of Polymer-Doxorubicin Nanoprodrug. Small 2018;14:1802403. [DOI: 10.1002/smll.201802403] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 10.7] [Reference Citation Analysis]
117 Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38:614-622. [PMID: 28344323 DOI: 10.1038/aps.2017.5] [Cited by in Crossref: 209] [Cited by in F6Publishing: 228] [Article Influence: 52.3] [Reference Citation Analysis]
118 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1942] [Article Influence: 707.3] [Reference Citation Analysis]
119 Sieghart W, Pinter M, Reisegger M, Müller C, Ba-Ssalamah A, Lammer J, Peck-Radosavljevic M. Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. Eur Radiol. 2012;22:1214-1223. [PMID: 22215073 DOI: 10.1007/s00330-011-2368-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
120 Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: The present and the future. World J Hepatol 2017; 9(21): 907-920 [PMID: 28824742 DOI: 10.4254/wjh.v9.i21.907] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 18.0] [Reference Citation Analysis]
121 Kocaturk NM, Akkoc Y, Kig C, Bayraktar O, Gozuacik D, Kutlu O. Autophagy as a molecular target for cancer treatment. Eur J Pharm Sci 2019;134:116-37. [PMID: 30981885 DOI: 10.1016/j.ejps.2019.04.011] [Cited by in Crossref: 67] [Cited by in F6Publishing: 73] [Article Influence: 33.5] [Reference Citation Analysis]
122 Matsuda Y, Ichida T, Fukumoto M. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol 2011;44:117-24. [PMID: 21922382 DOI: 10.1007/s00795-011-0547-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
123 Abdel-Rahman O, Cheung WY. The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:4763832. [PMID: 30159302 DOI: 10.1155/2018/4763832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
124 Srimuninnimit V, Sriuranpong V, Suwanvecho S. Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study: Sorafenib and gemcitabine in hepatoma. Asia-Pac J Clin Oncol 2014;10:255-60. [DOI: 10.1111/ajco.12191] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
125 Kovacovicova K, Vinciguerra M. Isolation of senescent cells by iodixanol (OptiPrep) density gradient-based separation. Cell Prolif 2019;52:e12674. [PMID: 31517418 DOI: 10.1111/cpr.12674] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
126 Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D'Angelica MI, Allen PJ, Erinjeri JP, Brody LA, O'Neill GP, Johnson KN, Garcia AR, Beattie C, Zhao B, Solomon SB, Schwartz LH, DeMatteo R, Abou-Alfa GK. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol. 2016;34:2046-2053. [PMID: 26834067 DOI: 10.1200/jco.2015.64.0821] [Cited by in Crossref: 181] [Cited by in F6Publishing: 83] [Article Influence: 36.2] [Reference Citation Analysis]
127 Erhardt A, Kolligs F, Dollinger M, Schott E, Wege H, Bitzer M, Gog C, Lammert F, Schuchmann M, Walter C, Blondin D, Ohmann C, Häussinger D. TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. Cancer Chemother Pharmacol 2014;74:947-54. [DOI: 10.1007/s00280-014-2568-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
128 Eatrides J, Wang E, Kothari N, Kim R. Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma. Cancer Control. 2017;24:1073274817729243. [PMID: 28975834 DOI: 10.1177/1073274817729243] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
129 Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. a systematic review and pooled analysis. Clin Oncol (R Coll Radiol). 2014;26:488-496. [PMID: 24856442 DOI: 10.1016/j.clon.2014.04.031] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
130 Abouelezz K, Khanapara D, Batiha GE, Ahmed EA, Hetta HF. Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries. Cancer Manag Res 2020;12:12239-48. [PMID: 33273860 DOI: 10.2147/CMAR.S280631] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Pacella CM, Francica G, Di Costanzo GG. Laser ablation for small hepatocellular carcinoma. Radiol Res Pract. 2011;2011:595627. [PMID: 22191028 DOI: 10.1155/2011/595627] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
132 Lee JS, Kim JH, Park YY, Mills GB. Systems biology approaches to decoding the genome of liver cancer. Cancer Res Treat 2011;43:205-11. [PMID: 22247704 DOI: 10.4143/crt.2011.43.4.205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
133 Duffy A, Wilkerson J, Greten TF. Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology 2013;57:1068-77. [PMID: 23112096 DOI: 10.1002/hep.26120] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
134 Connell LC, Harding JJ, Abou-Alfa GK. Advanced Hepatocellular Cancer: the Current State of Future Research. Curr Treat Options Oncol. 2016;17:43. [PMID: 27344158 DOI: 10.1007/s11864-016-0415-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
135 Qu K, Liu T, Lin T, Zhang X, Cui R, Liu S, Meng F, Zhang J, Tai M, Wan Y, Liu C. Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? Oncotarget 2016;7:67650-60. [PMID: 27588502 DOI: 10.18632/oncotarget.11767] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
136 Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430-3446. [PMID: 27622302 DOI: 10.1002/cncr.30237] [Cited by in Crossref: 106] [Cited by in F6Publishing: 108] [Article Influence: 21.2] [Reference Citation Analysis]
137 Ferrarese A, Sciarrone SS, Pellone M, Shalaby S, Battistella S, Zanetto A, Germani G, Russo FP, Senzolo M, Burra P, Gambato M. Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. Minerva Gastroenterol 2021;67. [DOI: 10.23736/s2724-5985.20.02775-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Lurje I, Werner W, Mohr R, Roderburg C, Tacke F, Hammerich L. In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Front Immunol 2021;12:650486. [PMID: 34025657 DOI: 10.3389/fimmu.2021.650486] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Gao HJ, Xu L, Zhang YJ, Chen MS. Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review. Chin J Cancer 2014;33:259-64. [PMID: 24325788 DOI: 10.5732/cjc.013.10133] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
140 Qi WX, Tang LN, Sun YJ, He AN, Lin F, Shen Z, Yao Y. Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials. Ann Oncol 2013;24:2943-52. [PMID: 23921791 DOI: 10.1093/annonc/mdt292] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
141 Qi WX, Shen Z, Tang LN, Yao Y. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis. Crit Rev Oncol Hematol 2014;92:71-82. [PMID: 24878433 DOI: 10.1016/j.critrevonc.2014.04.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
142 Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma. J Pathol. 2018;245:297-310. [PMID: 29604056 DOI: 10.1002/path.5083] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
143 Khan AA, Liu ZK, Xu X. Recent advances in immunotherapy for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00124-7. [PMID: 34344612 DOI: 10.1016/j.hbpd.2021.06.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Sim HW, Knox J, Dawson LA. An Update on Randomized Clinical Trials in Hepatocellular Carcinoma. Surg Oncol Clin N Am 2017;26:647-66. [PMID: 28923223 DOI: 10.1016/j.soc.2017.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
145 Cidon EU. Systemic treatment of hepatocellular carcinoma: Past, present and future. World J Hepatol 2017; 9(18): 797-807 [PMID: 28706578 DOI: 10.4254/wjh.v9.i18.797] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
146 Venkatramani R, Furman WL, Fuchs J, Warmann SW, Malogolowkin MH. Current and future management strategies for relapsed or progressive hepatoblastoma. Paediatr Drugs 2012;14:221-32. [PMID: 22702740 DOI: 10.2165/11597740-000000000-00000] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
147 Brown S, Nhola L, Herrmann J. Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems-Based Approaches: Systems Biology of TKIs. Clin Pharmacol Ther 2017;101:65-80. [DOI: 10.1002/cpt.552] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
148 Chao TI, Tai WT, Hung MH, Tsai MH, Chen MH, Chang MJ, Shiau CW, Chen KF. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. Cancer Lett. 2016;371:205-213. [PMID: 26679051 DOI: 10.1016/j.canlet.2015.11.039] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
149 Chen J, Jin R, Zhao J, Liu J, Ying H, Yan H, Zhou S, Liang Y, Huang D, Liang X, Yu H, Lin H, Cai X. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Letters 2015;367:1-11. [DOI: 10.1016/j.canlet.2015.06.019] [Cited by in Crossref: 111] [Cited by in F6Publishing: 122] [Article Influence: 18.5] [Reference Citation Analysis]
150 Colombo M, Raoul J, Lencioni R, Galle PR, Zucman-rossi J, Bañares R, Seehofer D, Neuhaus P, Johnson P. Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. European Journal of Gastroenterology & Hepatology 2013;25:639-51. [DOI: 10.1097/meg.0b013e32835e33bb] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
151 Li Y, Liang XY, Yue YQ, Sheng L, Liu JK, Wang ZY, Chen G. Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials. Tumour Biol 2016;37:6297-306. [PMID: 26619847 DOI: 10.1007/s13277-015-4493-9] [Reference Citation Analysis]
152 Gao Y, Wang PX, Cheng JW, Sun YF, Hu B, Guo W, Zhou KQ, Yin Y, Li YC, Wang J, Huang JF, Qiu SJ, Zhou J, Fan J, Yang XR. Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score-matched survival analysis. Cancer Med 2019;8:6933-44. [PMID: 31566899 DOI: 10.1002/cam4.2556] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
153 Wu Y, Sun T, Tang J, Liu Y, Li F. Ultrasound-Targeted Microbubble Destruction Enhances the Antitumor Efficacy of Doxorubicin in a Mouse Hepatocellular Carcinoma Model. Ultrasound Med Biol 2020;46:679-89. [PMID: 31882167 DOI: 10.1016/j.ultrasmedbio.2019.09.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
154 Wrzesinski SH, Taddei TH, Strazzabosco M. Systemic therapy in hepatocellular carcinoma. Clin Liver Dis 2011;15:423-41, vii-x. [PMID: 21689622 DOI: 10.1016/j.cld.2011.03.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
155 Hsu CH, Shen YC, Shao YY, Hsu C, Cheng AL. Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. J Hepatocell Carcinoma 2014;1:85-99. [PMID: 27508178 DOI: 10.2147/JHC.S45040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
156 Chang AY, Wang M. In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma. Anticancer Drugs. 2013;24:251-259. [PMID: 23187461 DOI: 10.1097/cad.0b013e32835ba289] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
157 Kobayashi S, Wada H, Hama N, Akita H, Kawamoto K, Eguchi H, Umeshita K, Doki Y, Mori M, Nagano H. Evaluation of safety parameters and changes in serum concentration in liver transplant recipients treated with doxorubicin during the anhepatic period. Cancer Chemother Pharmacol 2013;72:1325-33. [DOI: 10.1007/s00280-013-2311-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
158 Saffo S, Taddei TH. Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Dig Dis Sci. 2019;64:1016-1029. [PMID: 30887150 DOI: 10.1007/s10620-019-05582-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
159 Riha R, Gupta-Saraf P, Bhanja P, Badkul S, Saha S. Stressed Out - Therapeutic Implications of ER Stress Related Cancer Research. Oncomedicine 2017;2:156-67. [PMID: 29445586 DOI: 10.7150/oncm.22477] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
160 Fornaro L, Vivaldi C, Caparello C, Sacco R, Rotella V, Musettini G, Luchi S, Baldini EE, Falcone A, Masi G. Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. Future Oncol. 2014;10:285-304. [PMID: 24490614 DOI: 10.2217/fon.13.181] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
161 Ciombor KK, Feng Y, Benson AB, Su Y, Horton L, Short SP, Kauh JS, Staley C, Mulcahy M, Powell M. Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs. 2014;32:1017-1027. [PMID: 24890858 DOI: 10.1007/s10637-014-0111-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
162 Iansante V, Choy PM, Fung SW, Liu Y, Chai JG, Dyson J, Del Rio A, D'Santos C, Williams R, Chokshi S, Anders RA, Bubici C, Papa S. PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation. Nat Commun. 2015;6:7882. [PMID: 26258887 DOI: 10.1038/ncomms8882] [Cited by in Crossref: 107] [Cited by in F6Publishing: 105] [Article Influence: 17.8] [Reference Citation Analysis]
163 Zarębska I, Gzil A, Durślewicz J, Jaworski D, Antosik P, Ahmadi N, Smolińska-Świtała M, Grzanka D, Szylberg Ł. The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers. Clin Res Hepatol Gastroenterol 2021;45:101664. [PMID: 33667731 DOI: 10.1016/j.clinre.2021.101664] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Peng S, Zhao Y, Xu F, Jia C, Xu Y, Dai C. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma. PLoS One. 2014;9:e112530. [PMID: 25460347 DOI: 10.1371/journal.pone.0112530] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
165 Waterhouse DN, Yapp D, Verreault M, Anantha M, Sutherland B, Bally MB. Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy. Nanomedicine (Lond) 2011;6:1645-54. [PMID: 22077466 DOI: 10.2217/nnm.11.140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
166 da Fonseca LG, Reig M, Bruix J. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. Clin Liver Dis 2020;24:719-37. [PMID: 33012455 DOI: 10.1016/j.cld.2020.07.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
167 Ma YT, Palmer DH. Impact of restricting access to high-cost medications for hepatocellular carcinoma. Expert Rev Pharmacoecon Outcomes Res 2012;12:465-73. [PMID: 22971033 DOI: 10.1586/erp.12.33] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
168 Nguyen K, Jack K, Sun W. Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. Diseases 2015;4:E1. [PMID: 28933381 DOI: 10.3390/diseases4010001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
169 Man YN, Liu XH, Wu XZ. Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma. Chin J Integr Med 2015;21:49-57. [PMID: 25533651 DOI: 10.1007/s11655-014-1767-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
170 Qi WX, Fu S, Zhang Q, Guo XM. Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol. 2015;114:289-295. [PMID: 25497556 DOI: 10.1016/j.radonc.2014.11.033] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 9.0] [Reference Citation Analysis]
171 Cabrera R. Systemic targeted therapy beyond sorafenib. Clin Liver Dis (Hoboken) 2012;1:212-6. [PMID: 31186890 DOI: 10.1002/cld.128] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
172 Abou-alfa GK, Jarnagin W, Lowery M, D'angelica M, Brown K, Ludwig E, Covey A, Kemeny N, Goodman KA, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2014. pp. 1373-1396.e8. [DOI: 10.1016/b978-1-4557-2865-7.00080-1] [Reference Citation Analysis]
173 Elting LS, Chang Y, Parelkar P, Boers-doets CB, Michelet M, Hita G, Rouleau T, Cooksley C, Halm J, Vithala M, Bossi P, Escalante C, Brennan MT; On behalf of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Support Care Cancer 2013;21:3243-54. [DOI: 10.1007/s00520-013-1821-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
174 Manov I, Pollak Y, Broneshter R, Iancu TC. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib - the role of extracellular signal-regulated kinase counteraction: Sorafenib inhibits doxorubicin-induced autophagy. FEBS Journal 2011;278:3494-507. [DOI: 10.1111/j.1742-4658.2011.08271.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
175 Xu J, Ji L, Liang Y, Wan Z, Zheng W, Song X, Gorshkov K, Sun Q, Lin H, Zheng X, Chen J, Jin RA, Liang X, Cai X. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct Target Ther 2020;5:298. [PMID: 33361760 DOI: 10.1038/s41392-020-00375-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 21.0] [Reference Citation Analysis]
176 Knox JJ, Qin R, Strosberg JR, Tan B, Kaubisch A, El-Khoueiry AB, Bekaii-Saab TS, Rousey SR, Chen HX, Erlichman C. A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2015;33:241-246. [PMID: 25318437 DOI: 10.1007/s10637-014-0169-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
177 Zhang X, Zhou H, Jing W, Luo P, Qiu S, Liu X, Zhu M, Liang C, Yu M, Tu J. The Circular RNA hsa_circ_0001445 Regulates the Proliferation and Migration of Hepatocellular Carcinoma and May Serve as a Diagnostic Biomarker. Dis Markers. 2018;2018:3073467. [PMID: 29785229 DOI: 10.1155/2018/3073467] [Cited by in Crossref: 33] [Cited by in F6Publishing: 45] [Article Influence: 11.0] [Reference Citation Analysis]
178 Mikhail S, Cosgrove D, Zeidan A. Hepatocellular carcinoma: systemic therapies and future perspectives. Expert Rev Anticancer Ther. 2014;14:1205-1218. [PMID: 25199765 DOI: 10.1586/14737140.2014.949246] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
179 Ghatalia P, Je Y, Mouallem NE, Nguyen PL, Trinh QD, Sonpavde G, Choueiri TK. Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 2015;93:257-76. [PMID: 25523486 DOI: 10.1016/j.critrevonc.2014.11.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
180 Wang ZX, Li J, Wang EX, Xia DD, Bai W, Wang QH, Yuan J, Li XM, Niu J, Yin ZX, Xia JL, Fan DM, Han GH. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization. World J Gastroenterol 2020; 26(15): 1805-1819 [PMID: 32351295 DOI: 10.3748/wjg.v26.i15.1805] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
181 Khare T, Khare S, Ibdah JA. Proteomics approaches for early detection and targeted therapy of hepatocellular carcinoma. World J Gastrointest Oncol 2017; 9(1): 1-3 [PMID: 28144394 DOI: 10.4251/wjgo.v9.i1.1] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
182 Harding JJ, Abou-Alfa GK. Treating advanced hepatocellular carcinoma: How to get out of first gear. Cancer. 2014;120:3122-3130. [PMID: 24898783 DOI: 10.1002/cncr.28850] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
183 Poursaid A, Jensen MM, Nourbakhsh I, Weisenberger M, Hellgeth JW, Sampath S, Cappello J, Ghandehari H. Silk-Elastinlike Protein Polymer Liquid Chemoembolic for Localized Release of Doxorubicin and Sorafenib. Mol Pharmaceutics 2016;13:2736-48. [DOI: 10.1021/acs.molpharmaceut.6b00325] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
184 Liao SC, Hsu WH, Huang ZY, Chuang KL, Lin KT, Tseng CL, Tsai TH, Dao AH, Su CL, Huang CF. Bioactivity Evaluation of a Novel Formulated Curcumin. Nutrients 2019;11:E2982. [PMID: 31817577 DOI: 10.3390/nu11122982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
185 Desai JR, Ochoa S, Prins PA, He AR. Systemic therapy for advanced hepatocellular carcinoma: an update. J Gastrointest Oncol 2017;8:243-55. [PMID: 28480064 DOI: 10.21037/jgo.2017.02.01] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 9.3] [Reference Citation Analysis]
186 Park JG, Park SY, Lee HW. Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy. World J Gastroenterol 2015; 21(8): 2568-2572 [PMID: 25741170 DOI: 10.3748/wjg.v21.i8.2568] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
187 Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol 2015; 7(3): 362-376 [PMID: 25848464 DOI: 10.4254/wjh.v7.i3.362] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 12.3] [Reference Citation Analysis]
188 Xie B, Wang DH, Spechler SJ. Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci. 2012;57:1122-1129. [PMID: 22451120 DOI: 10.1007/s10620-012-2136-1] [Cited by in Crossref: 79] [Cited by in F6Publishing: 81] [Article Influence: 8.8] [Reference Citation Analysis]
189 Gao Y, Fan X, Li N, Du C, Yang B, Qin W, Fu J, Markowitz GJ, Wang H, Ma J, Cheng S, Yang P. CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma. Pharmacol Res 2020;157:104800. [PMID: 32278046 DOI: 10.1016/j.phrs.2020.104800] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
190 White LA, Menzin J, Korn JR, Friedman M, Lang K, Ray S. Medical care costs and survival associated with hepatocellular carcinoma among the elderly. Clin Gastroenterol Hepatol 2012;10:547-54. [PMID: 22210536 DOI: 10.1016/j.cgh.2011.12.031] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
191 Malarvizhi GL, Retnakumari AP, Nair S, Koyakutty M. Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma. Nanomedicine. 2014;10:1649-1659. [PMID: 24905399 DOI: 10.1016/j.nano.2014.05.011] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 7.1] [Reference Citation Analysis]
192 Chua CW, Choo SP. Targeted therapy in hepatocellular carcinoma. Int J Hepatol 2011;2011:348297. [PMID: 21994852 DOI: 10.4061/2011/348297] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
193 Yeh MM, Yeung RS, Apisarnthanarax S, Bhattacharya R, Cuevas C, Harris WP, Hon TLK, Padia SA, Park JO, Riggle KM, Daoud SS. Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol 2015; 7(11): 1460-1483 [PMID: 26085907 DOI: 10.4254/wjh.v7.i11.1460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
194 Woo HY, Heo J. Sorafenib in liver cancer. Expert Opin Pharmacother. 2012;13:1059-1067. [PMID: 22519770 DOI: 10.1517/14656566.2012.679930] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
195 Hutchinson L. Doxorubicin and sorafenib improves survival in patients with advanced hepatocellular carcinoma. Nat Rev Clin Oncol 2011;8:61-61. [DOI: 10.1038/nrclinonc.2010.208] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
196 Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol 2015; 7(4): 673-687 [PMID: 25866604 DOI: 10.4254/wjh.v7.i4.673] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 9.7] [Reference Citation Analysis]
197 Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr Oncol Rep. 2012;14:257-266. [PMID: 22434314 DOI: 10.1007/s11912-11012-10233-11910] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
198 Chan SL, Wong AM, Lee K, Wong N, Chan AK. Personalized therapy for hepatocellular carcinoma: Where are we now? Cancer Treatment Reviews 2016;45:77-86. [DOI: 10.1016/j.ctrv.2016.02.008] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
199 Ladekarl M, Villadsen GE, Rudbeck AR, Aagenæs O, Nielsen JE, Hamilton-Dutoit S, Nordsmark M. Advanced hepatocellular carcinoma in adolescence associated with congenital cholestasis: a case description. Case Rep Oncol 2013;6:98-103. [PMID: 23626552 DOI: 10.1159/000348715] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
200 [DOI: 10.1101/668350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
201 Psyrri A, Arkadopoulos N, Vassilakopoulou M, Smyrniotis V, Dimitriadis G. Pathways and targets in hepatocellular carcinoma. Expert Review of Anticancer Therapy 2014;12:1347-57. [DOI: 10.1586/era.12.113] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
202 Jian C, Tu MJ, Ho PY, Duan Z, Zhang Q, Qiu JX, DeVere White RW, Wun T, Lara PN, Lam KS, Yu AX, Yu AM. Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. Oncotarget 2017;8:30742-55. [PMID: 28415566 DOI: 10.18632/oncotarget.16372] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
203 Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: Evidence based treatment. World J Gastroenterol 2014; 20(18): 5442-5460 [PMID: 24833875 DOI: 10.3748/wjg.v20.i18.5442] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 79] [Article Influence: 13.3] [Reference Citation Analysis]
204 Sho T, Nakanishi M, Morikawa K, Ohara M, Kawagishi N, Izumi T, Umemura M, Ito J, Nakai M, Suda G, Ogawa K, Chuma M, Meguro T, Nakamura M, Nagasaka A, Horimoto H, Yamamoto Y, Sakamoto N. A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma. Drugs R D 2017;17:381-8. [PMID: 28573606 DOI: 10.1007/s40268-017-0187-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
205 Sampat KR, O'Neil B. Antiangiogenic therapies for advanced hepatocellular carcinoma. Oncologist 2013;18:430-8. [PMID: 23576483 DOI: 10.1634/theoncologist.2012-0388] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
206 Saavedra E, Hollebecque A, Soria JC, Hartl DM. Dysphonia induced by anti-angiogenic compounds. Invest New Drugs 2014;32:774-82. [PMID: 24343672 DOI: 10.1007/s10637-013-0049-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
207 Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011;2:135-64. [PMID: 21411864 DOI: 10.18632/oncotarget.240] [Cited by in Crossref: 381] [Cited by in F6Publishing: 368] [Article Influence: 38.1] [Reference Citation Analysis]
208 Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr Oncol Rep. 2012;14:257-266. [PMID: 22434314 DOI: 10.1007/s11912-012-0233-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
209 Abou-alfa GK, Jarnagin W, El Dika I, D'angelica M, Lowery M, Brown K, Ludwig E, Kemeny N, Covey A, Crane CH, Harding J, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1314-1341.e11. [DOI: 10.1016/b978-0-323-47674-4.00077-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
210 Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19-37. [PMID: 24367230 DOI: 10.2147/hmer.s16316] [Cited by in Crossref: 39] [Cited by in F6Publishing: 132] [Article Influence: 4.3] [Reference Citation Analysis]
211 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3499] [Article Influence: 404.7] [Reference Citation Analysis]
212 Duan W, Liu Y. Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib. Drug Des Devel Ther 2018;12:2149-61. [PMID: 30034219 DOI: 10.2147/DDDT.S166402] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 6.7] [Reference Citation Analysis]
213 Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, Pawlik TM, Tsung A, Cloyd JM. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 2019; 25(28): 3704-3721 [PMID: 31391767 DOI: 10.3748/wjg.v25.i28.3704] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 35] [Article Influence: 20.0] [Reference Citation Analysis]
214 Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. J Gastrointest Oncol. 2017;8:256-265. [PMID: 28480065 DOI: 10.21037/jgo.2016.09.07] [Cited by in Crossref: 90] [Cited by in F6Publishing: 94] [Article Influence: 22.5] [Reference Citation Analysis]
215 Zhong J, Xiang B, Ma L, Li L. Conventional oral systemic chemotherapy for postoperative hepatocellular carcinoma: A systematic review. Mol Clin Oncol 2014;2:1091-6. [PMID: 25279203 DOI: 10.3892/mco.2014.337] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
216 Zhai B, Sun XY. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 2013; 5(7): 345-352 [PMID: 23898367 DOI: 10.4254/wjh.v5.i7.345] [Cited by in Crossref: 121] [Cited by in F6Publishing: 110] [Article Influence: 15.1] [Reference Citation Analysis]
217 Funakoshi T, Latif A, Galsky MD. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials. Cancer Treat Rev 2014;40:636-47. [PMID: 24629273 DOI: 10.1016/j.ctrv.2014.02.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
218 Patel A, Sun W. Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future. Curr Treat Options Oncol. 2014;15:380-394. [PMID: 24838298 DOI: 10.1007/s11864-014-0291-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
219 Lee JK, Abou-Alfa GK. An update on clinical trials in the treatment of advanced hepatocellular carcinoma. J Clin Gastroenterol 2013;47 Suppl:S16-9. [PMID: 23751800 DOI: 10.1097/MCG.0b013e31827d77a2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
220 El Dika I, Capanu M, Chou JF, Harding JJ, Ly M, Hrabovsky AD, Do RKG, Shia J, Millang B, Ma J, O'Reilly EM, Abou-Alfa GK. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. Cancer Med 2020;9:7453-9. [PMID: 32841541 DOI: 10.1002/cam4.3389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
221 Goldstein R, Yu D, Gillmore R, Thirlwell C, O'Donoghue P, Mayer A, Meyer T. Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review. Future Oncol 2014;10:2007-14. [PMID: 25209630 DOI: 10.2217/fon.14.108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
222 Hagihara A, Ikeda M, Ueno H, Morizane C, Kondo S, Nakachi K, Mitsunaga S, Shimizu S, Kojima Y, Suzuki E, Katayama K, Imanaka K, Tamai C, Inaba Y, Sato Y, Kato M, Okusaka T. Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma. Cancer Sci 2014;105:354-8. [PMID: 24438504 DOI: 10.1111/cas.12353] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
223 Sonpavde G, Je Y, Schutz F, Galsky MD, Paluri R, Rosenberg JE, Bellmunt J, Choueiri TK. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 2013;87:80-9. [PMID: 23317774 DOI: 10.1016/j.critrevonc.2012.12.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
224 Beljanski V, Lewis CS, Smith CD. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther 2011;11:524-34. [PMID: 21258214 DOI: 10.4161/cbt.11.5.14677] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 6.8] [Reference Citation Analysis]
225 Lee S, Kim JH, Moon H, Lee HJ, Han JK. Combined treatment of sorafenib and doxorubicin-loaded microbubble-albumin nanoparticle complex for hepatocellular carcinoma: A feasibility study. PLoS One 2020;15:e0243815. [PMID: 33306731 DOI: 10.1371/journal.pone.0243815] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
226 Pang C, Miao H, Zuo Y, Guo N, Sun D, Li B. C/EBPβ enhances efficacy of sorafenib in hepatoblastoma. Cell Biol Int 2021;45:1897-905. [PMID: 33945665 DOI: 10.1002/cbin.11624] [Reference Citation Analysis]
227 Li JQ, Wu X, Gan L, Yang XL, Miao ZH. Hypoxia induces universal but differential drug resistance and impairs anticancer mechanisms of 5-fluorouracil in hepatoma cells. Acta Pharmacol Sin 2017;38:1642-54. [PMID: 28713155 DOI: 10.1038/aps.2017.79] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
228 Escalante CP, Chang YC, Liao K, Rouleau T, Halm J, Bossi P, Bhadriraju S, Brito-Dellan N, Sahai S, Yusuf SW, Zalpour A, Elting LS;  Epidemiology Section of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer; 2013. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer. 2016;24:4057-4074. [PMID: 27344327 DOI: 10.1007/s00520-016-3310-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
229 Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Japanese Journal of Clinical Oncology 2018;48:103-14. [DOI: 10.1093/jjco/hyx180] [Cited by in Crossref: 78] [Cited by in F6Publishing: 79] [Article Influence: 19.5] [Reference Citation Analysis]
230 Chan SL, Wong C, Lau CPY, Zhou Q, Hui CWC, Lui VWY, Ma BBY, Chan ATC, Yeo W. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. Cancer Chemother Pharmacol 2013;71:1417-25. [DOI: 10.1007/s00280-013-2139-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
231 Cuestas ML, Oubiña JR, Mathet VL. Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement. World J Pharmacol 2015; 4(1): 96-116 [DOI: 10.5497/wjp.v4.i1.96] [Cited by in CrossRef: 2] [Article Influence: 0.3] [Reference Citation Analysis]
232 Jiang SS, Tang Y, Zhang YJ, Weng DS, Zhou ZG, Pan K, Pan QZ, Wang QJ, Liu Q, He J, Zhao JJ, Li J, Chen MS, Chang AE, Li Q, Xia JC. A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. Oncotarget. 2015;6:41339-41349. [PMID: 26515587 DOI: 10.18632/oncotarget.5463] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 7.6] [Reference Citation Analysis]
233 Chong DQ, Tan IB, Choo SP, Toh HC. The evolving landscape of therapeutic drug development for hepatocellular carcinoma. Contemp Clin Trials 2013;36:605-15. [PMID: 23591326 DOI: 10.1016/j.cct.2013.03.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
234 Bertino G, Di Carlo I, Ardiri A, Calvagno GS, Demma S, Malaguarnera G, Bertino N, Malaguarnera M, Toro A, Malaguarnera M. Systemic therapies in hepatocellular carcinoma: present and future. Future Oncol. 2013;9:1533-1548. [PMID: 24106903 DOI: 10.2217/fon.13.171] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
235 Hosseinzadeh F, Verdi J, Ai J, Hajighasemlou S, Seyhoun I, Parvizpour F, Hosseinzadeh F, Iranikhah A, Shirian S. Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review. Cancer Cell Int 2018;18:133. [PMID: 30214375 DOI: 10.1186/s12935-018-0624-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
236 Deng GL, Zeng S, Shen H. Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World J Hepatol 2015; 7(5): 787-798 [PMID: 25914779 DOI: 10.4254/wjh.v7.i5.787] [Cited by in Crossref: 101] [Cited by in F6Publishing: 96] [Article Influence: 16.8] [Reference Citation Analysis]
237 Keino D, Yokosuka T, Hirose A, Sakurai Y, Nakamura W, Fujita S, Hayashi A, Miyagawa N, Iwasaki F, Hamanoue S, Yanagimachi M, Shiomi M, Goto S, Kitagawa N, Tanaka M, Nozawa K, Tanaka Y, Goto H. Pilot study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancer (FINEX pilot study). Pediatr Blood Cancer 2020;67:e28655. [PMID: 32798298 DOI: 10.1002/pbc.28655] [Reference Citation Analysis]
238 Qi WX, Min DL, Shen Z, Sun YJ, Lin F, Tang LN, He AN, Yao Y. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int J Cancer 2013;132:2967-74. [PMID: 23225494 DOI: 10.1002/ijc.27979] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 6.7] [Reference Citation Analysis]
239 Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP, De Toni EN, Wang X. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther 2020;5:87. [PMID: 32532960 DOI: 10.1038/s41392-020-0187-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 35.0] [Reference Citation Analysis]
240 Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. Expert Rev Anticancer Ther 2014;14:751-60. [PMID: 24666215 DOI: 10.1586/14737140.2014.894465] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
241 Wörns MA, Galle PR. Sorafenib for the treatment of hepatocellular carcinoma. Hepat Oncol 2014;1:189-204. [PMID: 30190954 DOI: 10.2217/hep.13.20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
242 Kiruthiga C, Devi KP, Nabavi SM, Bishayee A. Autophagy: A Potential Therapeutic Target of Polyphenols in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E562. [PMID: 32121322 DOI: 10.3390/cancers12030562] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 21.0] [Reference Citation Analysis]
243 Ruan Y, Sun L, Hao Y, Wang L, Xu J, Zhang W, Xie J, Guo L, Zhou L, Yun X, Zhu H, Shen A, Gu J. Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma. J Clin Invest 2012;122:2554-66. [PMID: 22653060 DOI: 10.1172/JCI58488] [Cited by in Crossref: 83] [Cited by in F6Publishing: 52] [Article Influence: 9.2] [Reference Citation Analysis]
244 Hamed O, Kimchi ET, Sehmbey M, Gusani NJ, Kaifi JT, Staveley-O’Carroll K. Impact of genetic targets on cancer therapy: hepatocellular cancer. Adv Exp Med Biol. 2013;779:67-90. [PMID: 23288636 DOI: 10.1007/978-1-4614-6176-0_4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
245 Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G; SARAH Trial Group. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Trials 2014;15:474. [PMID: 25472660 DOI: 10.1186/1745-6215-15-474] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
246 Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2011;98:1210-1224. [PMID: 21766289 DOI: 10.1002/bjs.7669] [Cited by in Crossref: 170] [Cited by in F6Publishing: 166] [Article Influence: 17.0] [Reference Citation Analysis]
247 Liu Y, Yue H, Xu S, Wang F, Ma N, Li K, Qiao L, Wang J. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. Int J Clin Oncol. 2015;20:952-959. [PMID: 25712158 DOI: 10.1007/s10147-015-0796-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
248 Sideras K, Bots SJ, Biermann K, Sprengers D, Polak WG, IJzermans JN, de Man RA, Pan Q, Sleijfer S, Bruno MJ, Kwekkeboom J. Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area.Br J Cancer. 2015;112:1911-1920. [PMID: 26057582 DOI: 10.1038/bjc.2015.92] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
249 Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, McCubrey JA, Montalto G. Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle. 2012;11:2843-2855. [PMID: 22801548 DOI: 10.4161/cc.21193] [Cited by in Crossref: 85] [Cited by in F6Publishing: 91] [Article Influence: 9.4] [Reference Citation Analysis]
250 Qi WX, Shen Z, Tang LN, Yao Y. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol 2014;78:748-62. [PMID: 24661224 DOI: 10.1111/bcp.12387] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 9.7] [Reference Citation Analysis]
251 Cheung TT, Kwok PC, Chan S, Cheung CC, Lee AS, Lee V, Cheng HC, Chia NH, Chong CCN, Lai TW, Law ALY, Luk MY, Tong CC, Yau TCC. Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. Liver Cancer 2018;7:40-54. [PMID: 29662832 DOI: 10.1159/000485984] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
252 Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E;  ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238-iv255. [PMID: 30285213 DOI: 10.1093/annonc/mdy308] [Cited by in Crossref: 230] [Cited by in F6Publishing: 206] [Article Influence: 115.0] [Reference Citation Analysis]
253 Inoue H, Hwang SH, Wecksler AT, Hammock BD, Weiss RH. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther 2011;12:827-36. [PMID: 21878748 DOI: 10.4161/cbt.12.9.17680] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 4.5] [Reference Citation Analysis]
254 Ghione S, Mabrouk N, Paul C, Bettaieb A, Plenchette S. Protein kinase inhibitor-based cancer therapies: Considering the potential of nitric oxide (NO) to improve cancer treatment. Biochem Pharmacol 2020;176:113855. [PMID: 32061562 DOI: 10.1016/j.bcp.2020.113855] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
255 Vogl TJ, Lee C. Doxorubicin -eluting beads in the treatment of liver carcinoma. Expert Opin Pharmacother 2014;15:115-20. [PMID: 24215628 DOI: 10.1517/14656566.2014.855719] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
256 Gong XL, Qin SK. Progress in systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(29): 6582-6594 [PMID: 27547002 DOI: 10.3748/wjg.v22.i29.6582] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
257 Li X, Wan J, Wu Z, Tu J, Hu Y, Wu S, Lou L. Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 2018;12:3043-9. [PMID: 30271119 DOI: 10.2147/DDDT.S151241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
258 Teng Y, Litchfield LM, Ivanova MM, Prough RA, Clark BJ, Klinge CM. Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor. Mol Cell Endocrinol 2014;392:23-36. [PMID: 24845419 DOI: 10.1016/j.mce.2014.05.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
259 Palmer DH, Johnson PJ. Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma. Cancer Metastasis Rev 2015;34:497-509. [DOI: 10.1007/s10555-015-9580-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
260 Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31:1631-1639. [PMID: 23547075 DOI: 10.1200/jco.2012.44.1659] [Cited by in Crossref: 445] [Cited by in F6Publishing: 215] [Article Influence: 55.6] [Reference Citation Analysis]
261 Chan DL, Morris DL, Chua TC. Clinical efficacy and predictors of outcomes of repeat hepatectomy for recurrent hepatocellular carcinoma - a systematic review. Surg Oncol 2013;22:e23-30. [PMID: 23535302 DOI: 10.1016/j.suronc.2013.02.009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
262 Wright GP, Marsh JW, Varma MK, Doherty MG, Bartlett DL, Chung MH. Liver Resection After Selective Internal Radiation Therapy with Yttrium-90 is Safe and Feasible: A Bi-institutional Analysis. Ann Surg Oncol. 2017;24:906-913. [PMID: 27878478 DOI: 10.1245/s10434-016-5697-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
263 Yang J, Yu H, Shen M, Wei W, Xia L, Zhao P. N1-guanyl-1,7-diaminoheptane sensitizes bladder cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2 activation. Cancer Sci. 2014;105:219-227. [PMID: 24262005 DOI: 10.1111/cas.12328] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
264 Deng X, Luo S, Luo X, Hu M, Ma F, Wang Y, Zhou L, Huang R. Fraction From Lycium barbarum Polysaccharides Reduces Immunotoxicity and Enhances Antitumor Activity of Doxorubicin in Mice. Integr Cancer Ther 2018;17:860-6. [PMID: 29355051 DOI: 10.1177/1534735417753544] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
265 Weiss A, Gill J, Goldberg J, Lagmay J, Spraker-Perlman H, Venkatramani R, Reed D. Advances in therapy for pediatric sarcomas. Curr Oncol Rep. 2014;16:395. [PMID: 24894064 DOI: 10.1007/s11912-014-0395-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
266 Posadas K, Ankola A, Yang Z, Yee NS. Tumor Molecular Profiling for an Individualized Approach to the Treatment of Hepatocellular Carcinoma: A Patient Case Study. Biomedicines 2018;6:E46. [PMID: 29673151 DOI: 10.3390/biomedicines6020046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
267 Li J, Liu W, Zhu W, Wu Y, Wu B. Transcatheter hepatic arterial chemoembolization and sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials. Oncotarget. 2017;8:59601-59608. [PMID: 28938663 DOI: 10.18632/oncotarget.19334] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
268 Ch’ang HJ. Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol 2015; 7(16): 2029-2040 [PMID: 26261692 DOI: 10.4254/wjh.v7.i16.2029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
269 Petrillo M, Scambia G, Ferrandina G. Novel targets for VEGF-independent anti-angiogenic drugs. Expert Opin Investig Drugs 2012;21:451-72. [PMID: 22339615 DOI: 10.1517/13543784.2012.661715] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
270 陈鹏, 李菲. 肝细胞癌诊治的新起点. 世界华人消化杂志 2012; 20(36): 3719-3724 [DOI: 10.11569/wcjd.v20.i36.3719] [Reference Citation Analysis]
271 Matsuda Y, Fukumoto M. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol 2011;44:183-9. [PMID: 22179180 DOI: 10.1007/s00795-011-0558-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
272 Hu QD, Chen W, Yan TL, Ma T, Chen CL, Liang C, Zhang Q, Xia XF, Liu H, Zhi X, Zheng XX, Bai XL, Yu XZ, Liang TB. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells. Cancer Lett 2012;325:207-13. [PMID: 22781398 DOI: 10.1016/j.canlet.2012.07.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
273 Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599-616. [PMID: 30061739 DOI: 10.1038/s41571-018-0073-4] [Cited by in Crossref: 482] [Cited by in F6Publishing: 497] [Article Influence: 241.0] [Reference Citation Analysis]
274 Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, Porter G, Kachura JR, Rasuli P, Gill S, Ghali P, Chaudhury P, Siddiqui J, Valenti D, Weiss A, Wong R. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 2011;18:228-40. [PMID: 21980250 DOI: 10.3747/co.v18i5.952] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
275 Yin X, Xiao Y, Han L, Zhang B, Wang T, Su Z, Zhang N. Ceramide-Fabricated Co-Loaded Liposomes for the Synergistic Treatment of Hepatocellular Carcinoma. AAPS PharmSciTech 2018;19:2133-43. [DOI: 10.1208/s12249-018-1005-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
276 Welker MW, Trojan J. Anti-angiogenesis in hepatocellular carcinoma treatment: Current evidence and future perspectives. World J Gastroenterol 2011; 17(26): 3075-3081 [PMID: 21912449 DOI: 10.3748/wjg.v17.i26.3075] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
277 Zhang QL, Yang JJ, Zhang HS. Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy. Biomed Pharmacother 2019;109:71-83. [PMID: 30396094 DOI: 10.1016/j.biopha.2018.07.037] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]